Faculty profile

Penelope Bradbury

Back to faculty

ProfessorDepartment of MedicineUniversity of Toronto

Penelope Bradbury

Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
8 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

480

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC.
JTO clinical and research reports · 2026
Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience.
JTO clinical and research reports · 2026
Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors.
JTO clinical and research reports · 2025

All 18 publications

Latest funding

Unconventional Innate-like T cells and Innate Lymphoid Cells as a Foundation for Novel Immunotherapeutic and Adoptive Cell Therapy Strategies in Metastatic Non-Small Cell Lung Cancer
CIHR · 2023 · Co-investigator
$1,000,000
Predictive biomarkers for adjuvant immune checkpoint inhibitor therapy in non-small cell lung cancer
CIHR · 2022 · Co-investigator
$1,224,000

All 2 grants and awards

18 publications.

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC.

Munarriz BJ, Khan S, Hueniken K, Tam S, Patel D, Zhan L, Brown C, Eng L, Sacher A, Bradbury P, Leighl N, Liu G, Shepherd FA

JTO clinical and research reports20261 citationsOpen Access

DOI: 10.1016/j.jtocrr.2025.100918 PMID: 41479841

Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience.

Fan KY, Ku M, Munarriz BJ, Stockley T, Rabinovitch A, Liu G, Bradbury P, Leighl NB

JTO clinical and research reports2026

DOI: 10.1016/j.jtocrr.2026.101056 PMID: 42751032

Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors.

Alghabban A, Corke L, Katzberg H, Bril V, Barnett-Tapia C, Mason W, Alothman R, Albiruni Ryan AR, Hogg D, Sridhar S, Dhani N, Spreafico A, Eng L, Sacher A, Bradbury P, Liu G, Leighl N, Shepherd FA

JTO clinical and research reports20255 citationsOpen Access

DOI: 10.1016/j.jtocrr.2024.100772 PMID: 40242666

Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World Setting.

Mittal A, Everest L, Patel D, Zhan LJ, Brown MC, Zaeimi F, Schmid S, Khan K, Dietrich K, Balaratnam K, de Santayana MGP, Eng L, Sacher AG, Shepherd FA, Leighl NB, Cho J, De Perrot M, Liu G, Bradbury P

JTO clinical and research reports20251 citationsSenior authorOpen Access

DOI: 10.1016/j.jtocrr.2025.100802 PMID: 40486487

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2024

DOI: 10.1200/jco.24.00720 PMID: 38843488

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A

The Lancet2023120 citations

DOI: 10.1016/s0140-6736(23)01613-6

Response to a Letter Received Entitled: "'Brief Report: Canadian Cancer Trials Group IND.227': Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma".

Piccirillo MC, Chu Q, Bradbury P, Seymour L

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2023Open Access

DOI: 10.1016/j.jtho.2023.03.003 PMID: 37210189

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.

Kuang S, Fung AS, Perdrizet KA, Chen K, Li JJN, Le LW, Cabanero M, Karsaneh OAA, Tsao MS, Morganstein J, Ranich L, Smith AC, Wei C, Cheung C, Shepherd FA, Liu G, Bradbury P, Pal P, Schwock J, Sacher AG, Law JH, Stockley TL, Leighl NB

Current oncology (Toronto, Ont.)202223 citationsOpen Access

DOI: 10.3390/curroncol29070352 PMID: 35877212

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.

Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G

Lung cancer (Amsterdam, Netherlands)202043 citations

DOI: 10.1016/j.lungcan.2020.05.018 PMID: 32521388

Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.

de Perrot M, Wu L, Cabanero M, Perentes JY, McKee TD, Donahoe L, Bradbury P, Kohno M, Chan ML, Murakami J, Keshavjee S, Tsao MS, Cho BCJ

The Journal of thoracic and cardiovascular surgery202029 citationsOpen Access

DOI: 10.1016/j.jtcvs.2019.10.122 PMID: 31866087

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Penelope Bradbury

Research

Latest papers

Latest funding

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC.

Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience.

Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors.

Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World Setting.

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Response to a Letter Received Entitled: "'Brief Report: Canadian Cancer Trials Group IND.227': Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma".

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.

Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.

Unconventional Innate-like T cells and Innate Lymphoid Cells as a Foundation for Novel Immunotherapeutic and Adoptive Cell Therapy Strategies in Metastatic Non-Small Cell Lung Cancer

Predictive biomarkers for adjuvant immune checkpoint inhibitor therapy in non-small cell lung cancer

Frequent collaborators

Geoffrey Liu

Adrian Sacher

Ming Tsao

Natasha Leighl

Ming-Sound Tsao

Lawson Eng

Marc de Perrot

Lesley Seymour

Shaf Keshavjee

Michael Cabanero

John Cho

Dongsheng Tu

John Goffin

Tracy Stockley

Joseph Kim

Robert Heaton

Barbara-Ann Millar

Warren Mason

Laura Donahoe

Demetris Patsios

Ur Metser

Tao Wang

Normand Blais

Hans Katzberg

Carolina Barnett-Tapia

Tatiana Conrad

Wei Xu

Tony Reiman

Kazuhiro Yasufuku

David Dawe

Anna Spreafico

Andrew Hope

Alejandro Berlin

Stephen Welch

Rachel Goodwin

Jonathan Yeung